Literature DB >> 27340056

Genome Sequence of Vaccinia virus Strain Lister-Butantan, a Lister Vaccine Variant Used during a Smallpox Eradication Campaign in Brazil.

Felipe Assis1, Giliane Trindade1, Betânia Drumond1, Mike Frace2, Scott Sammons2, Ginny Emerson2, Yu Li2, Darin Carroll2, Dhwani Batra2, Jonatas Abrahão3, Erna Kroon1.   

Abstract

Here, we report the 187.8-kb genome sequence of Vaccinia virus Lister-Butantan, which was used in Brazil during the WHO smallpox eradication campaign. Its genome showed an average similarity of 98.18% with the original Lister isolate, highlighting the low divergence among related Vaccinia virus vaccine strains, even after several passages in animals and cell culture.
Copyright © 2016 Assis et al.

Entities:  

Year:  2016        PMID: 27340056      PMCID: PMC4919395          DOI: 10.1128/genomeA.00536-16

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Among strains used in the Smallpox Eradication Programme, Lister-derived strains were by far the most widely distributed around the world (1). Due to this, several different strains were generated in different countries, leading ultimately to a slightly divergent variants of the Lister Elstree original strain (LO) (2, 3). In Brazil, some laboratories received financial support for the development of freeze-dried vaccine production during earlier years of the national smallpox eradication campaign (1, 4). In this work, we report the genome sequence of vaccine Vaccinia virus strain Lister-Butantan (LBT), a strain largely used during the national smallpox eradication campaign in Brazil. The LBT genome was extracted using a BioRobot EZ1 workstation and the protocol to purify genomic DNA from tissue (Qiagen, Hilden, Germany). The DNA was used as a template for producing 20 overlapping PCR amplicons. The templates were sequenced by primer walking on both strands using Applied Biosystems BigDye 3.1 chemistry and ABI 3730XL automated DNA (Applied Biosystems, Coralville, IA). The resulting reads covered the genome in a 9-fold average redundancy at each base position. Chromatogram data were assembled using SeqMerge (Accelrys, Inc., Madison, WI), Phred/Phrap was used for base-calling and assembly software, and Consed was used for sequence editing. The FgenesV tool was used for gene prediction (http://www.softberry.com/). The functional annotations were performed using the Blast2GO platform (5). The genome annotation was manually revised. Predicted open reading frames (ORFs) <40 amino acids and with no hits in any database were ruled out. The LBT genome is a linear double-stranded DNA (dsDNA) molecule of 187,893 bp long, with a G+C content of 33.66%. This molecule was predicted to contain 222 ORFs, with size ranging from 40 to 1,286 amino acids (aa) (average length, 783 aa). The LBT and LO strains showed a mean amino acid identity of 99.47%. Moreover, we identified a total of 535 nucleotide substitutions, of which 206 (38.5%) were nonsynonymous. Phylogenetic analysis based on the central conserved region of the genome (81 kbp) revealed that LBT is related to Vaccinia virus (VV) strain Lister, commonly used in Europe during the smallpox eradication program (6). Regarding main differences between the LBT and LO strains, we highlight the single nucleotide polymorphisms (SNPs) and/or other kinds of polymorphisms in genes involved in: (i) evasion of host defense mechanisms or virulence: ORF 013 (serine protease inhibitor [SPI-1]), ORF 019 (interleukin 18 [IL-18] binding protein), M2L and K1L genes (NF-kB inhibitor protein), and B2R and B3R genes (“Schaflen genes” family); (ii) structural and enzyme proteins: ORF 103 (thymidine kinase), ORF 164 (ATPase/DNA packaging protein), ORF 182 (thymidylate kinase), ORF 189 (hemagglutinin protein), and ORF 033 (complement control protein—B5R in VACV-Cop); and (iii) proteins recognized by the immune system: ORF 099 (internal virion protein) and ORF 192 (serine-threonine kinase). Despite these polymorphisms, we conclude that these findings corroborate previous studies that showed a close relationship between the Lister-derived strains in terms of DNA and protein sequences, regardless of numerous historical passages and maintenance of vaccine stocks.

Nucleotide sequence accession number.

The genome sequence of VV strain Lister-Butantan was submitted to GenBank with the accession no. KX061501.
  5 in total

Review 1.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

2.  An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.

Authors:  Shigeru Morikawa; Tokuki Sakiyama; Hideki Hasegawa; Masayuki Saijo; Akihiko Maeda; Ichiro Kurane; Go Maeno; Junko Kimura; Chie Hirama; Teruhiko Yoshida; Yasuko Asahi-Ozaki; Tetsutaro Sata; Takeshi Kurata; Asato Kojima
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia Virus.

Authors:  Maria Luiza G Medaglia; Nissin Moussatché; Andreas Nitsche; Pjotr Wojtek Dabrowski; Yu Li; Inger K Damon; Carolina G O Lucas; Luciana B Arruda; Clarissa R Damaso
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

4.  Genomic sequence of a clonal isolate of the vaccinia virus Lister strain employed for smallpox vaccination in France and its comparison to other orthopoxviruses.

Authors:  Aude Garcel; Jean-Marc Crance; Robert Drillien; Daniel Garin; Anne-Laure Favier
Journal:  J Gen Virol       Date:  2007-07       Impact factor: 3.891

5.  Blast2GO: a universal tool for annotation, visualization and analysis in functional genomics research.

Authors:  Ana Conesa; Stefan Götz; Juan Miguel García-Gómez; Javier Terol; Manuel Talón; Montserrat Robles
Journal:  Bioinformatics       Date:  2005-08-04       Impact factor: 6.937

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.